SLNO NASDAQ
Redwood City, CA 94065
US
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Yen Kristen | D-Return | 37,639 | — | 2026-05-18 |
| Yen Kristen | D-Return | 1,741 | $44.25 | 2026-05-18 |
| Yen Kristen | D-Return | 4,999 | $24.00 | 2026-05-18 |
| Yen Kristen | D-Return | 4,000 | $25.05 | 2026-05-18 |
| Yen Kristen | D-Return | 666 | $51.15 | 2026-05-18 |